Nivolumab: An “immune storm” in a patient with history of myasthenia gravis
Open Access
- 2 November 2020
- journal article
- other
- Published by Elsevier BV in Neurología (English Edition)
- Vol. 35 (9), 692-694
- https://doi.org/10.1016/j.nrleng.2019.11.002
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Neuromuscular complications of immune checkpoint inhibitor therapyMuscle & Nerve, 2018
- Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune systemTherapeutic Advances in Neurological Disorders, 2018
- Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and ManagementCurrent Neurology and Neuroscience Reports, 2018
- Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectivesNature Reviews Neurology, 2017
- Nivolumab-related myasthenia gravis with myositis and myocarditis in JapanNeurology, 2017
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitorsEuropean Journal Of Cancer, 2017
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyEuropean Journal Of Cancer, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal Of Cancer, 2016
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.The Journal of Experimental Medicine, 1995